Palatin Technologies (PTN) Current Deferred Revenue (2011 - 2018)
Palatin Technologies' (PTN) quarterly Current Deferred Revenue came in at $500000.0 in Q2 2018, down 98.57% YoY from $35.1 million in Q2 2017, and down 14.61% on a QoQ basis from $585519.0 in Q1 2018.
Palatin Technologies (PTN) Current Deferred Revenue (2011 - 2018) Analysis & Trends
Palatin Technologies (PTN) has 4 years of Current Deferred Revenue data on file, last reported at $500000.0 in Q2 2018.
- Quarterly Current Deferred Revenue fell 98.57% year-over-year to $500000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $500000.0 (down 98.57% YoY) and the FY2018 annual result came in at $500000.0, down 98.57% from the prior year.
- Current Deferred Revenue fell to $500000.0 in Q2 2018, from $585519.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $53.8 million in Q1 2017 to a low of $500000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 500,000.00 |
| Mar 31, 2018 | 585,519.00 |
| Dec 31, 2017 | 9.55 Mn |
| Sep 30, 2017 | 20.16 Mn |
| Jun 30, 2017 | 35.05 Mn |
| Mar 31, 2017 | 53.83 Mn |
| Jun 30, 2012 | 37,217.00 |
| Dec 31, 2011 | 7,396.00 |
| Sep 30, 2011 | 18,888.00 |
| Jun 30, 2011 | 391,817.00 |